Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Director | August 26, 2026 | August 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date August 26, 2026 · Filed August 29, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-26 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2026-08-26 · Exercise / conversion · Acquired 2,055 · Balance 2,055 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Row 2 · 2026-08-26 · Exercise / conversion · Acquired 2,035 · Balance 4,090 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Row 3 · 2026-08-26 · Sale · Disposed 485 · Balance 3,605 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 4 · 2026-08-26 · Sale · Disposed 615 · Balance 2,990 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 5 · 2026-08-26 · Sale · Disposed 700 · Balance 2,290 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 6 · 2026-08-26 · Sale · Disposed 1,098 · Balance 1,192 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 7 · 2026-08-26 · Sale · Disposed 602 · Balance 590 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 8 · 2026-08-26 · Sale · Disposed 590 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2028-08-27 | Direct | 6,165 |
Reported balance
After 2026-08-26 transaction · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · 2026-08-26 · Exercise / conversion · Acquired 2,055 · Balance 6,165 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F2: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-06-30 | Direct | 8,140 |
Reported balance
After 2026-08-26 transaction · row 11
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 11 · 2026-08-26 · Exercise / conversion · Acquired 2,035 · Balance 8,140 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F3: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 11,486 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · Balance 11,486 F10: Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
F2: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
F3: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F10: Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2022 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 5,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 5,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013282 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,445 Underlying: Common Stock · 5,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,753 | $1.52 | $2,664.56 |
DisclosureSEC source: 0001654954-22-013282 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,779 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 5,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013282 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:05 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009136 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,511 Underlying: Common Stock · 8,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:05 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 3,083 | $2.30 | $7,087.82 |
DisclosureSEC source: 0001654954-22-009136 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,466 Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:05 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009136 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004489 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,424 Underlying: Common Stock · 1,221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 500 | $2.55 | $1,275.00 |
DisclosureSEC source: 0001654954-22-004489 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,636 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004489 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 61,532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001172 · section16.xml · derivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,645 Underlying: Common Stock · 61,532 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 81,395 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001172 · section16.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,395 Underlying: Common Stock · 81,395 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000128 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,461 Underlying: Common Stock · 1,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 505 | $3.21 | $1,621.05 |
DisclosureSEC source: 0001654954-22-000128 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,915 Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000128 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000127 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,652 Underlying: Common Stock · 1,221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 501 | $3.21 | $1,608.21 |
DisclosureSEC source: 0001654954-22-000127 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000127 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010719 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,873 Underlying: Common Stock · 1,221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 423 | $4.87 | $2,060.01 |
DisclosureSEC source: 0001654954-21-010719 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,469 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010719 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:13 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007597 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,094 Underlying: Common Stock · 2,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:13 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 823 | $5.89 | $4,847.47 |
DisclosureSEC source: 0001654954-21-007597 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:13 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007597 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:53 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 19,536 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000915 · section16.xml · derivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,228 Underlying: Common Stock · 19,536 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:53 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 27,427 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000915 · section16.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,427 Underlying: Common Stock · 27,427 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2021 and 1/48th monthly on the last day of each month thereafter. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:23 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 1,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000162 · section16.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,692 Underlying: Common Stock · 1,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:23 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 504 | $6.12 | $3,084.48 |
DisclosureSEC source: 0001654954-21-000162 · section16.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:23 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000162 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 02:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 20,455 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001654954-20-001796 · section16.xml · derivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,455 Underlying: Common Stock · 20,455 shares Expires 2030-01-31 F2 · derivative.exercise_date: Stock Options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 02:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 4,923 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-001796 · section16.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,923 Underlying: Common Stock · 4,923 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. F1 · derivative.expiration_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 23:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 325 | $8.00 | $2,600.00 |
DisclosureSEC source: 0001654954-19-014148 · section16.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325 Read SEC document |
| August 28, 2018 Filed Sep 27, 2018 23:10 UTC Amendment | Monopar Therapeutics NONE · Entity 5152 | GrantStock options · Derivative | 41,100 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010580 · section16.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,100 Underlying: Common Stock · 41,100 shares Expires 2028-08-27 F1 · derivative.exercise_date: Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
| August 28, 2018 Filed Sep 27, 2018 18:31 UTC | Monopar Therapeutics NONE · Entity 5152 | GrantStock options · Derivative | 41,100 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010546 · section16.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,620 Underlying: Common stock · 41,100 shares Expires 2028-08-27 F1 · derivative.exercise_date: Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.